A61K 38 - Medicinal preparations containing peptides

Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
10/2004
10/28/2004	WO2004091649A1 Acute respiratory syndromes
10/28/2004	WO2004091647A1 Compositions of active wnt protein
10/28/2004	WO2004091646A2 Use of slurp-1 for treating diseases related to acetylcholine receptors dysfunction
10/28/2004	WO2004091609A2 Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
10/28/2004	WO2004091592A2 Methods and compositions to treat myocardial conditions
10/28/2004	WO2004091584A1 Absorption enhancers such as e.g. bht, bha or propyl gallate
10/28/2004	WO2004091573A1 Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
10/28/2004	WO2004091572A2 Cochleate compositions directed against expression of proteins
10/28/2004	WO2004091552A2 Biodegradable glucosaminemuramyl peptides for apoptosis modulation
10/28/2004	WO2004091551A2 Anti-tumor vasculature effects of human serum albumin derivatives
10/28/2004	WO2004091550A2 Compositions and methods for delivering thymosin beta 4, analogues, isoforms and other derivatives
10/28/2004	WO2004091517A2 Conjugates comprising human il-18 and substitution mutants thereof
10/28/2004	WO2004091498A2 Alcohol-free transdermal insulin composition and processes for manufacture and use thereof
10/28/2004	WO2004091497A2 Methods and compositions for increasing the anaerobic working capacity in tissues
10/28/2004	WO2004091495A2 Compositions and methods related to production of erythropoietin
10/28/2004	WO2004091492A2 Computer-based model for identification and characterization of non-competitive inhibitors of nicotinic acetylcholine receptors and related ligand-gated ion channel receptors
10/28/2004	WO2004091490A2 Somatostatin-dopamine chimeric analogs
10/28/2004	WO2004091487A2 Hemophilia treatment by inhalation of coagulation factors
10/28/2004	WO2004091476A2 Method of screening remedy for heart disease and medicinal composition for treating heart disease
10/28/2004	WO2004091475A2 Gaucher disease drugs and methods of identifying same
10/28/2004	WO2004091438A2 Improved ophthalmic and contact lens solutions containing peptides as representative enhancers
10/28/2004	WO2004091436A2 Methods and compositions for treating ocular disease
10/28/2004	WO2004091388A1 LIVIN-SPECIFIC siRNAS FOR THE TREATMENT OF THERAPY-RESISTANT TUMORS
10/28/2004	WO2004091383A2 Breast endothelial cell expression patterns
10/28/2004	WO2004083375A3 Methods of promoting the differentiation of stem cells
10/28/2004	WO2004081229A3 Use of bv8 and/or eg-vegf to promote hematopoiesis
10/28/2004	WO2004076626A3 Methods of gene therapy for treating disorders of the ear by administering a vector encoding an atonal-associated factor
10/28/2004	WO2004074311A3 Human cyclooxygenase-3 and uses thereof
10/28/2004	WO2004073731A8 14-3-3 protein for prevention and treatment of fibroproliferative disorders
10/28/2004	WO2004072651A3 Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine 1f receptor (5-ht1f)
10/28/2004	WO2004071418A3 Compounds for the treatment of systemic lupus erythematosus
10/28/2004	WO2004067023A3 Survivin-derived peptides and use thereof
10/28/2004	WO2004062560A3 Pharmaceutical composition
10/28/2004	WO2004062555A3 Use of natriuretic peptides for the treatment of stature disorders related to the shox gene
10/28/2004	WO2004061456A3 Uses of hmgb, hmgn, hmga proteins
10/28/2004	WO2004058813A3 Peptides having a high cysteine content
10/28/2004	WO2004058798A9 Antimicrobial peptides
10/28/2004	WO2004058292A3 Methods and compositions for suppressing fibrocyte differentiation
10/28/2004	WO2004056857A3 Use of the multifunctional transcription factor yin-yang-1 and variants thereof for treating illnesses, especially type 1 diabetes
10/28/2004	WO2004055041A3 Defensin-inducing peptides from fusobacterium
10/28/2004	WO2004053057A3 Gene expression systems and recombinant cell lines
10/28/2004	WO2004052929A3 Recombinant cell line
10/28/2004	WO2004052922A3 Peptides, antibodies thereto, and their use in the treatment of central nervous system damage
10/28/2004	WO2004050885A3 Control of apoptosis using a complex of an oligonucleotide and a regulatory peptide
10/28/2004	WO2004050041A3 Butyrylcholinesterase variants that alter the activity of chemotherapeutic agents
10/28/2004	WO2004047766A3 Treatment for sma disease
10/28/2004	WO2004045520A3 Complement receptor 2 targeted complement modulators
10/28/2004	WO2004045496A3 Compositions and devices comprising or encoding the run x2 protein and method of use
10/28/2004	WO2004043481A3 Compositions containing peptide copper complexes and metalloproteinase inhibitors, and methods related thereto
10/28/2004	WO2004041857A3 Mutant of clostridium difficile toxin b and methods of use
10/28/2004	WO2004037205A3 LOW DOSE METHODS FOR TREATING DISORDERS IN WHICH TNFα ACTIVITY IS DETRIMENTAL
10/28/2004	WO2004032867A3 Molecules preferentially associated with effector t cells or regulatory t cells and methods of their use
10/28/2004	WO2004029197A3 Co-stimulatory molecules
10/28/2004	WO2004024936A3 Mutant forms of glutamate receptors mglur2 and mglur3
10/28/2004	WO2004024075A3 Chemokine receptor antagonists as therapeutic agents
10/28/2004	WO2004017919A3 Use of mullerian inhibiting substance and interferon for treating tumors
10/28/2004	WO2004016746A3 Methods of identifying compounds that modulate il-4 receptor-mediated ige synthesis utilizing a c-myc protein
10/28/2004	WO2004016148A3 Shiga toxin b-subunit as a vector for tumor diagnosis and drug delivery to gb3 expressing tumors
10/28/2004	WO2004013633A3 Method for isolating atp binding proteins by means of immobolized protein inhibitors
10/28/2004	WO2004013313A3 Antisense nucleic acids
10/28/2004	WO2004010848A8 Oncogenes useful for the identification of urinary bladder cancer
10/28/2004	WO2004003176A3 Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs
10/28/2004	WO2004001009A3 Apo-2 ligand/trail variants and uses thereof
10/28/2004	WO2004000228A3 Methods for preventing and treating microbial infections by modulating transcription factors
10/28/2004	WO2004000208A3 System and method for inhibiting cellular proliferation with tachykinins
10/28/2004	WO2003105908A3 Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs
10/28/2004	WO2003104415A3 Method to screen ligands using eukaryotic cell display
10/28/2004	WO2003104262A3 Gp41 peptides and methods based-thereon for inhibiting hiv fusion to target cells
10/28/2004	WO2003100005A3 Universal chimera bank
10/28/2004	WO2003099991A3 Glp-1 gene delivery for the treatment of type 2 diabetes
10/28/2004	WO2003087126A3 Heteroclitic analogs and related methods
10/28/2004	WO2003086298A3 Use of interleukin-19 to treat ovarian cancer
10/28/2004	WO2003082317A9 Peptide epitopes recognized by antigen specific cd8+ t lymphocytes
10/28/2004	WO2003077840A3 Method of modulating inflammatory response
10/28/2004	WO2003076490A8 Hydrophilic polymer derivate with y type branch and preparation method of it medical composite comprising above compound
10/28/2004	WO2003074007A3 Modulators of leukocyte activation, compositions, and methods of use
10/28/2004	WO2003072738A3 Beta chain-associated regulator of apoptosis
10/28/2004	WO2003072600A8 Methods of screening molecular libraries for active molecules that restore the function of target proteins and peptides that restore the function of mutant p53
10/28/2004	WO2003066825A3 Modified pituitary gland development in offspring from expectant mother animals treated with growth hormone releasing hormone therapy
10/28/2004	WO2003057827A3 Insulin-responsive dna binding protein-1 and methods to regulate insulin-responsive genes
10/28/2004	WO2003041635A3 Methods and compositions for therapeutic treatment of cathepsin k complex-mediated disorders
10/28/2004	WO2003026591A3 Modification of feeding behavior
10/28/2004	WO2003022882A3 Method of increasing the contractility of a heart, a heart muscle or cells of a heart muscle
10/28/2004	WO2003020954A3 205p1b5 in treatment and detection of cancer
10/28/2004	WO2002088322A3 Cell adhesion and extracellular matrix proteins
10/28/2004	WO2001081540A3 Growth factor which acts through erb b-4 rtk
10/28/2004	US20040215251 Genetic modification of targeted regions of the cardiac conduction system
10/28/2004	US20040215007 Comprises nucleotide sequences coding polypeptide for use in identifying modulators for treatment of cell proliferative, nervous system and inflammatory diseases
10/28/2004	US20040215006 Oligonucleotide sequences for treatment and prevention of cell proliferative and skin disorders; gene expression inhibition; antisense agents
10/28/2004	US20040214998 siderophores; batch affinity chromatography; for detecting antibiotic resistance
10/28/2004	US20040214997 includes growth factors and extracellular matrix molecules flexibly tethered to a support medium; used to stimulate cell and tissue growth by enhancment of the biological response to the growth factor; liver cells
10/28/2004	US20040214996 Multimeric peptides/immunoglobulins for use in the treatment of bone disorders
10/28/2004	US20040214995 Melanoma antigens and their use in diagnostic and therapeutic methods
10/28/2004	US20040214993 Monoclonal antibody for use in prevention and treatment of cell proliferative disorders; immunotherapy; antitumor agents
10/28/2004	US20040214990 Transmembrane protein differentially expressed in cancer
10/28/2004	US20040214871 Treating cancer with a synergistic mixtures; anticarcinogenic agents; epothilone has secondary amide instead of an ester
10/28/2004	US20040214854 Cardiovascular compositions and methods using combinations of anti-platelet agents
10/28/2004	US20040214851 increasing gene expression by contacting with compound comprising imidazoquinoline amine, then contacting with opiod growth factor; pain/scarring reduction
10/28/2004	US20040214849 via injection or intravenous drip
10/28/2004	US20040214846 A heteroaryl carbamic acid, secondary amide or amine, or phthalimidoyl derivatives; prevent from getting the disease or condition; cognitive impairment, Down's syndrome, Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type, cerebral amyloid angiopathy, neurodegenerative disease

1 ... 1543 1544 1545 1546 1547 1548 1549 1550 1551 1552 1553 1554 1555 1556 1557 1558 1559 1560 1561 1562 1563 ... 3163